Adaptimmune Therapeutics PLC (ADAP)
1.07
+0.01
(+0.94%)
USD |
NASDAQ |
Apr 26, 12:19
Adaptimmune Therapeutics Total Liabilities (Quarterly): 243.10M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 243.10M |
September 30, 2023 | 208.51M |
June 30, 2023 | 216.33M |
March 31, 2023 | 204.20M |
December 31, 2022 | 247.04M |
September 30, 2022 | 218.86M |
June 30, 2022 | 246.35M |
March 31, 2022 | 256.65M |
December 31, 2021 | 263.58M |
September 30, 2021 | 112.54M |
June 30, 2021 | 111.85M |
March 31, 2021 | 102.42M |
December 31, 2020 | 109.92M |
September 30, 2020 | 102.82M |
June 30, 2020 | 104.62M |
March 31, 2020 | 99.20M |
December 31, 2019 | 57.90M |
September 30, 2019 | 60.57M |
Date | Value |
---|---|
June 30, 2019 | 52.53M |
March 31, 2019 | 50.78M |
December 31, 2018 | 29.85M |
September 30, 2018 | 33.47M |
June 30, 2018 | 46.20M |
March 31, 2018 | 55.81M |
December 31, 2017 | 78.16M |
September 30, 2017 | 72.39M |
June 30, 2017 | 54.78M |
March 31, 2017 | 57.65M |
December 31, 2016 | 68.37M |
September 30, 2016 | 42.64M |
June 30, 2016 | 42.57M |
March 31, 2016 | 42.61M |
September 30, 2015 | 46.63M |
December 31, 2014 | 45.85M |
June 30, 2014 | 53.11M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
52.53M
Minimum
Jun 2019
263.58M
Maximum
Dec 2021
158.90M
Average
112.54M
Median
Sep 2021
Total Liabilities (Quarterly) Benchmarks
Biodexa Pharmaceuticals Plc | 7.470M |
NuCana PLC | 16.46M |
Autolus Therapeutics PLC | 263.91M |
Mereo BioPharma Group PLC | 15.96M |
TC BioPharm (Holdings) PLC | 7.957M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 282.62M |
Shareholders Equity (Quarterly) | 39.51M |
Current Ratio | 2.852 |